Research and Clinical Trials

Title  
Lilly I4T-MC-JVDJ: An Open-Label, Multicenter, Phase 1 Study of Ramucirumab Plus MEDI4736 in Patients With Locally Advanced and Unresectable or Metastatic Gastrointestinal or Thoracic Malignancies
Brief Description  
Objectives Endpoints Phase 1a and 1b Primary: To assess the safety and tolerability of ramucirumab in combination with MEDI4736 Dose-limiting toxicities, observed for 1 treatment cycle (21 days for NSCLC and 28 days for Gastric-GEJ and HCC) Safety (including but not limited to): TEAEs, SAEs, deaths, and clinical laboratory abnormalities per CTCAE (Version 4.0) Secondary: To assess the PK of ramucirumab and MEDI4736 when co-administered PK: Cmin and approximate Cmax of ramucirumab and MEDI
Who may be Eligible  
Please contact us for eligibility criteria.
Speciality/Disorder  
Lung
Status  
OPEN
Start Date  
08/24/2016
IRB Number  
00017215
Principal Investigator  
Hwang, Jimmy John
Contact Name  
Donna Acampora

For More Information, Contact  Donna  , Acampora
Phone:  980-442-2319 Fax:    
Email:  Donna.Acampora@carolinashealthcare.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, 28204
Close